Skip to content

Efficacy study of HP749, 20mg versus placebo in patients with OAB- UG058-0204

Efficacy study of HP749, 20mg versus placebo in patients with OAB-UG058-0204 (Over active bladders).

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12605000584639
Acronym
UG058-0204
Enrollment
210
Registered
2005-10-04
Start date
2006-08-06
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

HP749

Sponsors

UroGene SA
Lead SponsorCommercial sector/Industry

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used)

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

History of at least 6 months of OAB symptoms, defined as at least 8 micturitions/day, one urgency with or without incontinence episode (at least one/day) and nocturia (to wake at night > 1 time to void). Patients without medication for OAB, or with ineffective and/or unsatisfactory medication for OAB or with a history of ineffective and/or unsatisfactory medication for OAB are included in the trial (wash-out of 2 weeks is mandatory before base-line period and urodynamic examination). Prerequisites for inclusion are no previous bladder training or no current bladder training if started less than one month prior to the trial. Patients with polyuria, urodynamic stress incontinence, renal disease, or bladder outlet obstruction are excluded from the trial, as are patients having any other disease or condition (including neurological disease that could be linked to OAB symptoms) making them unsuitable for participating to the trial.

Exclusion criteria

No exclusion criteria

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026